Two Phase 3 trials testing the investigational oral therapy fenebrutinib in people with multiple sclerosis (MS) have hit ...

Roche's experimental multiple sclerosis drug achieved its main goal in one of two key late-stage trials testing it against ...

Roche's late-stage trial of fenebrutinib, a multiple sclerosis drug candidate, met its primary goal. The trial demonstrated a significant reduction in annualized relapse rates compared to ...

By Ludwig Burger FRANKFURT (Reuters) -Swiss drugmaker Roche said on Monday that a late-stage trial testing its multiple ...

The company is evaluating the use of fully human intranasal anti-CD3 monoclonal antibody foralumab for the treatment of patients with Secondary Progressive Multiple Sclerosis in a phase 2a study. The ...

BioNxt Solutions Inc. (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT), a bioscience company developing next-generation drug delivery technologies, has launched a 15-day dosing optimization study for its lead ...

Request To Download Free Sample of This Strategic Report @ The symptoms of multiple sclerosis differ widely, subject to the extent of damage and the number of neurons affected. Some of the symptoms ...

VANCOUVER, BC / ACCESS Newswire / August 20, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery ...